Interactive Discussions
Engage in in-depth discussions with industry experts and your peers about the progress, trends and challenges you face in your research!
Interactive discussion groups play an integral role in networking with potential collaborators. They provide an opportunity to share examples from your work, vet ideas with peers, and be part of a group problem-solving endeavor.
These will take place IN-PERSON ONLY.
TUESDAY, AUGUST 19
7:30 am Interactive Discussions with Continental Breakfast
Interactive Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Discussions page on the conference website for a complete listing of topics and descriptions.
BREAKOUT DISCUSSION: Best Practice Recommendations by the IFCC Committee on Mobile Health and Bioengineering in Laboratory Medicine
James Nichols, PhD, DABCC, FADLM, Professor of Pathology, Microbiology, and Immunology; Medical Director, Clinical Chemistry and POCT, Vanderbilt University School of Medicine
- Identify common types of personal health devices
- Describe the data collected by health devices
- Recognize the advantages of interfacing personal health data with a patient’s electronic medical record
- Debate the challenges of connecting health devices to an EMR
BREAKOUT DISCUSSION: Integrating AI and Machine Learning into IVD Products
Giles Sanders, DPhil, Head, Diagnostics, TTP plc
Lawrence Worden, Founder, Principal, IVD Logix
Even beyond the hype, we are seeing a technological shift enabled by AI and ML disrupting professions and whole industries. In vitro diagnostics will also see changes from the broader upheavals that AI will bring. This open breakout discussion looks to consider how AI may impact us in POCDX in the future. Areas we may touch on include:
- Where AI may be applied in the diagnostic development pathway
- How AI-enabled tools may enable better diagnostics
- How multianalyte and longitudinal data could be applied for personalization of diagnostic approaches
- Regulatory and other hurdles to overcome
BREAKOUT DISCUSSION: Guidance and Considerations for Diagnostic Workups following Positive MCED Results
Christos Patriotis, PhD, Program Director, Cancer Biomarkers Research Group, NIH NCI
BREAKOUT DISCUSSIONS: Funding and Commercialization Resources for Early Cancer Detection
Linda K. Zane, PhD, Program Director, SBIR Development Center, National Cancer Institute
BREAKOUT DISCUSSIONS: Challenges with Screening Rate Data and Approaches to Improve Novel Early Cancer Screening Test Development
Gary Gustavsen, PhD, Partner & Managing Director, Health Advances
- Challenges around existing cancer screening rate data sources – inaccuracy, inaccessibility, incompleteness
- Impact of these challenges on early detection test development
- Proposed solutions and opportunities to get involved
BREAKOUT DISCUSSIONS: What is the Optimal Number of Cancers for Which an MCED Should be Trained?
Sam Hanash, MD, PhD, Director, Red & Charline McCombs Institute; Evelyn & Sol Rubenstein Distinguished Chair, Cancer Prevention; Professor, Clinical Cancer Prevention-Research, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- Trade-offs between sensitivity and specificity
- The pros and cons of broad vs. more narrow initial training
- Accounting for patient risk for more targeted screening
WEDNESDAY, AUGUST 20
7:30 am Interactive Discussions with Continental BreakfastEnabling Point-of-Care Diagnostics
Interactive Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Discussions page on the conference website for a complete listing of topics and descriptions.
BREAKOUT DISCUSSION: The Role of CRISPR Technology in the Future of Clinical Diagnostics
Gregory Brett Robb, PhD, Senior Scientific Director & Head, CRISPR Science, VedaBio, Inc.
- Sample preparation—is it needed?
- Selection of amplification versus amplification-free CRISPR methods
- Selection of the optimal Cas enzymes
- Selection and evaluation of guide sequences
BREAKOUT DISCUSSION: What Future Syndromic Panels Are Needed in the Clinical Laboratory?
Niaz Banaei, MD, Professor, Pathology and Medicine; Medical Director, Stanford Health Care Clinical Microbiology Laboratory; Director, Stanford Clinical Microbiology Fellowship; Associate Program Director, Stanford Clinical Pathology Residency Training, Stanford University School of Medicine
- Met needs for syndromic panels
- Unmet needs for syndromic panels
- Challenges for industry to develop future syndromic panels
- Regulatory changes for future syndromic panels
BREAKOUT DISCUSSION: Have We Finally Reached a Tipping Point for Digital/Computational Pathology?
Gary Gustavsen, PhD, Partner & Managing Director, Health Advances
Liam Lee, PhD, Senior Director of Medical Diagnostics, US Lung Cancer Diagnostics Team Lead, AstraZeneca
- Novel computational biomarkers in oncology
- Pharma pipeline driving need for computational pathology
- Key stakeholders across the ecosystem
BREAKOUT DISCUSSIONS: Funding and Commercialization Resources for Early Cancer Detection
Linda K. Zane, PhD, Program Director, SBIR Development Center, National Cancer Institute